The Biosimilars Council released a new analysis by IQVIA that reveals a PBM strategy to protect $2 billion in profits by “strangling” the biosimilar market and preventing savings for patients.
Following the transaction, Grown Alchemist will focus on large-scale partnerships and activations in lifestyle, music and retail to help drive international growth in key markets.
Migalastat Capsules are indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
The grants will support organizations in Phoenix working to increase equitable access to health care, address social determinants of health and educate the community on the effects of air pollution.
